US Stock MarketDetailed Quotes
NGNE Neurogene
- 43.770
- +1.510+3.57%
Trading Jul 22 15:18 ET
568.15MMarket Cap-15455P/E (TTM)
44.990High42.980Low51.70KVolume42.260Open42.260Pre Close2.27MTurnover0.87%Turnover RatioLossP/E (Static)12.98MShares53.00052wk High3.33P/B260.48MFloat Cap12.20052wk Low--Dividend TTM5.95MShs Float1115.000Historical High--Div YieldTTM4.76%Amplitude7.500Historical Low43.816Avg Price1Lot Size
About Neurogene Company
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
Company Profile
SymbolNGNE
Company NameNeurogene
Listing DateMar 7, 2014
Founded2007
CEOMr. Richard K. Matros
MarketNASDAQ
Employees91
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address535 West 24th Street,5th floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10011
Phone1-877-237-5020
Websitehttp://www.neurogene.com
Company Executives
- Name
- Position
- Salary
- Dr. Rachel McMinn, PhD
- Executive Chairman of the Board and Chief Executive Officer
- 1.08M
- Christine Mikail Cvijic, J.D.
- President and Chief Financial Officer
- 1.13M
- Dr. Stuart Cobb, PhD
- Chief Scientific Officer
- 784.32K
- Dr. Julie Jordan, M.D.
- Chief Medical Officer
- --
- Donna Cochener
- Senior Vice President and General Counsel
- --
- Dr. Cory Freedland, PhD
- Independent Director
- --
- Robert Keith Woods
- Independent Director
- --
- Dr. Sarah B. Noonberg, M.D.,PhD
- Independent Director
- 62.12K
- Dr. Robert A. Baffi,PhD
- Independent Director
- 64.08K
- Rohan Palekar
- Independent Director
- 71.62K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg